Sarcoma Treatment in Hyderabad — Expert Surgical Oncology Care Across 7 Locations

What Is Sarcoma?

Sarcomas are cancers that arise from connective tissues — the materials that hold the body together and support its structures. This includes muscle, fat, blood vessels, nerves, tendons, and the tissue that lines joints. Unlike the more common cancers (breast, colon, lung) which develop from the cells lining organs, sarcomas develop from the structural tissues between organs.

Sarcoma is an umbrella term for more than 50 distinct cancer types, which fall into two broad categories:

• Soft tissue sarcomas — cancers arising from muscle, fat, blood vessels, nerves, and other non-bone connective tissues. These account for about 80% of all sarcomas and most commonly appear in the arms, legs, and abdomen.
• Bone sarcomas — cancers arising from the bone itself. The three main types are osteosarcoma, Ewing sarcoma, and chondrosarcoma. These are covered in detail on CION's bone cancer treatment page.

Sarcomas are rare — they account for less than 1% of all adult cancers — which means many patients encounter clinicians who have seen only a handful of cases in their careers. This rarity is the primary reason that specialist oncology management, from the very first biopsy, is so important.

The Main Types of Soft Tissue Sarcoma — Why Subtype Matters

No local hospital treatment page in Hyderabad adequately explains the most important subtypes of soft tissue sarcoma in patient-friendly language — yet the subtype determines the entire treatment pathway. Here are the most clinically significant types:

Risk Factors for Soft Tissue Sarcoma

For most soft tissue sarcomas, no specific cause is identified. Known risk factors include:

• Inherited genetic conditions — Li-Fraumeni syndrome, neurofibromatosis type 1 (NF1), hereditary retinoblastoma, and familial adenomatous polyposis (FAP) each carry significantly increased risk of specific sarcoma types; genetic counselling is recommended when these conditions are present
• Previous radiation therapy — high-dose radiation given for another cancer can, in rare cases, cause a sarcoma in the treated area years later; radiation-induced sarcomas typically appear 5 to 10 years after the original treatment
• Chronic lymphoedema — long-standing swelling of the arm or leg (from lymph node removal or infection) rarely leads to a specific type of sarcoma affecting the blood vessels of the swollen limb
• Chemical exposure — exposure to certain industrial chemicals (vinyl chloride, dioxin, arsenic) is associated with a rare type of liver sarcoma in occupational settings

The large majority of sarcoma patients have none of these risk factors. For most, the cancer arises from chance errors in cell division within connective tissue cells.

Symptoms of Soft Tissue Sarcoma — What to Watch For

The most common presentation of soft tissue sarcoma is a lump — and the most dangerous aspect of sarcoma symptoms is that the lump is usually painless. A painless lump is easy to dismiss as harmless. Two characteristics should always prompt immediate specialist evaluation:

• A lump that is larger than 5cm (roughly the size of a golf ball) — sarcomas tend to be large at the time of first notice
• A lump that is deep to the skin surface — sitting within the muscle layer rather than immediately under the skin
• A lump that is growing over weeks or months

Other symptoms depend on location:

• Abdominal swelling, discomfort, or a sense of fullness — from retroperitoneal sarcomas that grow silently until very large
• Restricted movement in a nearby joint — from sarcomas in the limbs
• Abnormal bleeding — from uterine leiomyosarcoma, often initially resembling fibroids

Any lump that is large, deep, or growing should be evaluated with an MRI scan before any attempt at removal. Do not accept reassurance that a lump is 'probably benign' without imaging confirmation.

The Most Important Rule in Sarcoma Management — Plan the Biopsy Before Anything Else

Of all the rules in sarcoma management, this one matters most: never attempt to remove a suspected sarcoma without proper planning. This applies even when the lump appears benign, even when a local surgeon is confident it is harmless, and even when the patient is anxious to 'just get it out.'

Here is why: the tissue surrounding a sarcoma has what surgeons call a 'reactive zone' — a layer of tissue immediately around the tumour that may contain microscopic cancer cells that have spread beyond the main mass. When a sarcoma is removed without proper planning by a non-specialist, this reactive zone is disrupted. Cancer cells are spread through the surrounding tissue planes — into areas that were previously clean. The next surgical operation then has to remove not just where the tumour was, but all the contaminated tissue around it — which is often much larger, and sometimes involves vital structures that cannot safely be removed.

In some cases, an unplanned excision of a sarcoma converts a situation where limb-sparing surgery would have been possible into one where amputation becomes necessary. In others, it makes cure impossible.

How Is Sarcoma Diagnosed at CION?

CION's diagnostic pathway combines imaging and biopsy under one tumour board — so the right diagnosis, type, and stage are confirmed before any treatment decision is made.

MRI — the Essential First Scan

MRI is the imaging investigation of choice for soft tissue sarcomas. It shows the tumour's size, precise location, relationship to nearby muscles, blood vessels, nerves, and bone, and whether the tumour sits deep within the muscle layer. MRI findings guide biopsy planning and determine whether limb-sparing surgery is feasible.

CT Scan for Staging

A CT scan of the chest checks for spread to the lungs — the most common site of distant spread for most soft tissue sarcomas. A CT or MRI of the abdomen and pelvis is used for staging retroperitoneal sarcomas.

Core Needle Biopsy

A thick needle is inserted into the tumour — under ultrasound or CT guidance — and multiple tissue cores are taken for laboratory analysis. The needle track is positioned precisely so it can be excised as part of the subsequent surgery. The pathologist examines the cores to confirm the sarcoma type, grade, and specific subtype — which determines the treatment plan. For some retroperitoneal sarcomas, specific imaging appearances may allow the surgeon to proceed directly to surgery without biopsy.

PET-CT

PET-CT is used for selected sarcoma cases — particularly high-grade tumours — to check for metastatic disease at distant sites not visible on standard CT. PET-CT scans are arranged through CION's specialist imaging referral network, starting from ₹9,999 to ₹16,000.

Soft Tissue Sarcoma Staging and Survival

Soft tissue sarcoma is staged using the AJCC system, which combines tumour size, depth, grade (how aggressive the cells look under a microscope), and whether the cancer has spread. Grade is the most important prognostic factor for soft tissue sarcoma — more important than size alone.

Survival estimates reflect modern treatment at specialist sarcoma centres. Outcomes vary by subtype; rhabdomyosarcoma in children and GIST on imatinib have considerably better long-term outcomes than these averages. Every case is reviewed by CION's multidisciplinary tumour board before treatment begins.

Surgery for Soft Tissue Sarcoma — the Primary Treatment

Wide local excision — removing the tumour with a clear margin of healthy tissue on all sides — is the cornerstone of soft tissue sarcoma treatment. The surgical goal is to achieve 'R0 resection' — no cancer cells at the cut edge of the specimen. For limb sarcomas, this is limb-sparing surgery: the tumour is removed but the limb is preserved.

The margin achieved during surgery is the single strongest predictor of local recurrence. A tumour that has been incompletely removed (with cancer cells at the edge) has a much higher chance of coming back in the same area. This is why unplanned excision by a non-specialist surgeon — even when the operation appears technically successful — so often leads to recurrence.

Reconstruction after soft tissue sarcoma surgery varies by location. In the limbs, the remaining muscles and soft tissues are typically sufficient. In cases where the resection creates a significant defect, plastic surgery reconstruction using tissue from another area of the body may be coordinated.

Radiation Before Surgery — Shrinking the Tumour First

For large (typically >5cm) high-grade soft tissue sarcomas of the arm or leg, giving radiation therapy before surgery — rather than after — is now the preferred approach at specialist centres. This is called neoadjuvant radiation. The rationale:

Neoadjuvant radiation for sarcoma involves 5 weeks of daily IMRT treatment, followed by a 4 to 6 week recovery period before surgery. Post-surgery radiation (adjuvant radiation) remains the option when neoadjuvant treatment is not possible or when surgical margins are found to be close after the operation. CION's radiation oncology and surgical oncology teams plan this sequence together for every eligible patient.

Chemotherapy for Soft Tissue Sarcoma

Chemotherapy has a more limited and subtype-specific role in soft tissue sarcoma than in many other cancers. It is used in three main situations:

• For high-grade sarcomas that have spread to the lungs or other organs (Stage IV) — where systemic treatment is the primary approach
• As pre-surgery treatment (neoadjuvant) for selected high-grade sarcomas — to shrink the tumour before surgery alongside or instead of radiation
• For specific subtypes that are known to be chemotherapy-sensitive — rhabdomyosarcoma (highly sensitive), synovial sarcoma (moderately sensitive), Ewing sarcoma of soft tissue

The standard first-line chemotherapy for soft tissue sarcoma uses a medicine that works by damaging the DNA inside cancer cells, combined with another that prevents cancer cells from dividing — given together as intravenous infusions every 3 weeks. Response rates vary significantly: some sarcoma subtypes respond well; others (particularly well-differentiated liposarcoma and leiomyosarcoma) have limited chemotherapy sensitivity.

For advanced sarcoma after failure of first-line chemotherapy, a targeted medicine that helps cut off the blood supply tumours need to grow — called pazopanib — is approved for most soft tissue sarcoma subtypes (except GIST and liposarcoma) and has been shown to slow disease progression.

Retroperitoneal Sarcomas — a Distinct and Challenging Subtype

Retroperitoneal sarcomas develop in the space behind the abdominal organs. They grow silently and reach enormous sizes before causing symptoms — often discovered incidentally on a scan, or when a patient notices an abdominal mass. The most common types are liposarcoma and leiomyosarcoma. Three things make them different from limb sarcomas:

Local recurrence — the cancer coming back in the same area after surgery — is the most common cause of treatment failure for retroperitoneal sarcomas. For this reason, the surgical planning, the decision of how much adjacent tissue to remove along with the sarcoma, and the choice of surgical centre are all critically important.

Every Case Reviewed by a Specialist Team Before Treatment Begins

Sarcoma management requires surgical oncology, medical oncology, radiation oncology, and specialist sarcoma pathology working together from the time of the biopsy. At CION, every sarcoma case is reviewed by our multidisciplinary tumour board before any treatment begins:

• MRI reviewed to confirm tumour location, depth, and relationship to critical structures
• Biopsy needle track planned in coordination with the operating surgeon — correct positioning before any sampling
• Sarcoma subtype confirmed — GIST, rhabdomyosarcoma, synovial sarcoma, liposarcoma, leiomyosarcoma each have specific treatment implications
• Neoadjuvant vs adjuvant radiation decision for large high-grade limb sarcomas
• Limb-sparing feasibility assessed — MRI reviewed for proximity to major vessels and nerves
• Chemotherapy sensitivity evaluated by subtype — avoiding ineffective chemotherapy for non-responsive subtypes
• GIST correctly identified — imatinib pathway initiated; standard chemotherapy not used
• Retroperitoneal planning — extent of resection and adjacent organ involvement assessed
• Molecular profiling for selected subtypes where targeted therapy options exist
• PET-CT staging arranged through CION's specialist imaging referral network (₹9,999–₹16,000) for high-grade tumours
• NCCN and ESMO Protocol Adherence
• Digital coordination across all 7 Hyderabad locations

Sarcoma Treatment Cost in Hyderabad

Costs vary significantly based on the sarcoma type, size, location, and whether surgery alone or a combination of radiation and chemotherapy is required:

Costs are indicative. A personalised cost estimate is provided following your initial oncology consultation at CION.

Financial Support Options

• EMI Facility — flexible instalment-based payment options available for all patients
• Private Health Insurance — CION works with all major TPAs for cashless hospitalisation
• Government Schemes — Aarogyasri, CGHS, ECHS & ESI cashless support for eligible patients (subject to scheme coverage for the specific procedure)

Why Patients Choose CION for Sarcoma Treatment in Hyderabad

Nine reasons our patients pick CION — across AIIMS-trained surgical expertise, NCCN protocols, and dedicated second opinion services for sarcoma re-assessment.

Every Sarcoma Journey Begins with the Right First Step

If you have a lump that is larger than 5cm, deep beneath the skin, or growing — see a surgical oncologist before any attempt at removal. We walk this journey with you.